Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 15;15(7):315.
doi: 10.3390/jpm15070315.

Key Determinants Influencing Treatment Decision-Making for and Adherence to Active Surveillance for Prostate Cancer: A Systematic Review

Pani Nasseri  1   2 , Jorien Veldwijk  2 , Christa Niehot  1 , Esmee F H Mulder  1 , Esther W de Bekker-Grob  2 , Monique J Roobol  1 , Lionne D F Venderbos  1
Affiliations
Review

Key Determinants Influencing Treatment Decision-Making for and Adherence to Active Surveillance for Prostate Cancer: A Systematic Review

Pani Nasseri et al. J Pers Med. .

Abstract

Background/Objectives: Men choosing active surveillance (AS) for low- and intermediate risk prostate cancer (PCa) must weigh its harms and benefits against those of active treatment (AT). To understand factors influencing treatment decision-making (TDM) for and adherence to AS, we performed a systematic review. Methods: This systematic review followed the PRISMA guidelines and was registered with PROSPERO (ID CRD42024490427). A comprehensive search strategy from 1990 to 2024 was executed across multiple databases, including Medline and Embase. Studies were included if they examined factors influencing TDM for AS or active monitoring (AM) and adherence to AS/AM. Results: Of the 8316 articles identified, 223 articles were eligible for inclusion. The decision for AS was influenced by different factors, including comprehensive information about treatment options, social support, and wanting to avoid side-effects. Key reasons to choose AT over AS included a lack of information from healthcare professionals about AS and fear of disease progression. Reasons for adhering to the AS protocol included better quality of life and social support. While non-adherence to the AS protocol is prompted by, e.g., biopsy burden and uncertainty, AS discontinuation is generally a results of medical reasons (namely disease upgrading) or from anxiety and family pressure. Conclusions: Numerous factors influence men's treatment pathway choices. Involving family members in shared decision-making and ensuring that patients have detailed information about AS as a treatment option could help to improve AS uptake. Addressing psychosocial challenges through education and family involvement could improve AS adherence. These insights can help healthcare providers by addressing men's needs during TDM and AS.

Keywords: active surveillance; discontinuation; prostate cancer; treatment choice adherence; treatment decision.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart.
Figure 2
Figure 2
Factors influencing an active surveillance (AS) pathway in alphabetical order ** The percentages represent the proportion of studies reporting each factor. These percentages do not total 100%, as individual studies often addressed multiple factors.
See this image and copyright information in PMC

References

    1. Keyes M., Crook J., Morton G., Vigneault E., Usmani N., Morris W.J. Treatment options for localized prostate cancer. Can. Fam. Physician. 2013;59:1269. - PMC - PubMed
    1. Taylor K.L., Luta G., Hoffman R.M., Davis K.M., Lobo T., Zhou Y., Leimpeter A., Shan J., E Jensen R., Aaronson D.S., et al. Quality of life among men with low-risk prostate cancer during the first year following diagnosis: The PREPARE prospective cohort study. Transl. Behav. Med. 2018;8:156–165. doi: 10.1093/tbm/ibx005. - DOI - PMC - PubMed
    1. Carter H.B. Management of low (favourable)-risk prostate cancer. BJU Int. 2011;108:1684–1695. doi: 10.1111/j.1464-410X.2010.10489.x. - DOI - PMC - PubMed
    1. Bangma C.H., Roemeling S., Schröder F.H. Overdiagnosis and overtreatment of early detected prostate cancer. World J. Urol. 2007;25:3–9. doi: 10.1007/s00345-007-0145-z. - DOI - PMC - PubMed
    1. Aizer A.A., Gu X., Chen M.-H., Choueiri T.K., Martin N.E., Efstathiou J.A., Hyatt A.S., Graham P.L., Trinh Q.-D., Hu J.C., et al. Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States. J. Natl. Compr. Cancer Netw. 2015;13:61–68. doi: 10.6004/jnccn.2015.0009. - DOI - PubMed

Grants and funding

LinkOut - more resources